Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban vs dual antiplatelet therapy in acute branch atheromatous disease (BAD)
ChiCTR2600120890Phase 3Not yet recruiting
- Sponsor
- Chengdu Second People's Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirofiban in ischemic stroke (2 arms), sponsored by Chengdu Second People's Hospital. Primary endpoint: Proportion of patients with mRS 0–1 at 90 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600120890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120890.